David Kaslow

Vice President, Essential Medicines Director at PATH

David Kaslow

David Kaslow

Vice President, Essential Medicines Director at PATH

Overview
RelSci Relationships

2181

Birthday

1959

Age

60

Contact Data
Trying to get in touch with David Kaslow? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David Kaslow likely has professional access to. A relationship does not necessarily indicate a personal connection.

AmpliPhi Biosciences Corp.

Relationship likelihood: Average

Chief Medical Officer at Adamis Pharmaceuticals Corp.

Relationship likelihood: Average

Director, Market Dynamics at PATH

Relationship likelihood: Average

Country Director, Kenya at PATH

Relationship likelihood: Average

Program Leader, Malaria & Neglected Tropical Diseases at The Carter Center, Inc.

Relationship likelihood: Average

Director, Office of Research Ethics at PATH

Relationship likelihood: Average

Country Director, the Democratic Republic of the Congo at PATH

Relationship likelihood: Average

Country Director, Uganda at PATH

Relationship likelihood: Average

Country Director, Senegal at PATH

Relationship likelihood: Average

Director, Office of Scientific Affairs at PATH

Relationship likelihood: Average

Paths to David Kaslow
Potential Connections via
Relationship Science
You
David Kaslow
Vice President, Essential Medicines Director at PATH
Education
Medical Degree

Consistently ranked among the nation's top medical schools, the UCSF School of Medicine earns its greatest distinction from its outstanding faculty among them are four Nobel laureates, 75 Institute of Medicine members, 63 American Academy of Arts and Sciences members, 42 National Academy of Sciences members, and 17 Howard Hughes Medical Institute investigators.

Career History
Vice President, Essential Medicines Director
Current

Program for Appropriate Technology in Health provides social healthcare services. Its platform includes vaccines, drugs, diagnostics and devices. The firm offers treatment for malaria, pneumonia and diarrheal. The company was founded in 1977 and is headquartered in Seattle, WA.

Portfolio Manager
Prior - 2005

The foundation of BAPB's equity selection process is proprietary research. They use a blend of qualitative and quantitative fundamental research to target large capitalization companies that have long-term growth potential, proven earnings track records, competitive advantages and strong management. Fixed-income investments are tailored to address client-specific needs for income and capital appreciation.

Chief Scientific Officer
2001 - Prior

Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Our active independent and partnered development programs include: Infectious disease vaccines for use in high-risk populations Infectious disease vaccines for general pediatric, adolescent and adult populations Cancer vaccines or immunotherapies Gene-based delivery of angiogenic growth factors for treatment of cardiovascular diseases Headquartered in San Diego, CA, Vical is driven by 115 people from some 20 different countries. Vical is independently pioneering the development of paradigm-changing DNA vaccines and cancer immunotherapies, and is partnering with such industry leaders as Merck, sanofi-aventis, Novartis, Astellas, AnGes, Merial and the NIH. What’s in a Name? Vical initially was formed by former Hybritech executives Howard Greene and Timothy Wollaeger and UCSD professors Karl Hostetler and Douglas Richman to explore the development of lipid-based delivery of antiVIrals and CALcitonin – hence VICAL. A surprise outcome in an experiment - in which the lipid-free control performed better than the test lipid - led to the discovery of the core technology behind all of Vical’s current programs. The Vical mission changed as a result, but the Vical name endured

Other Affiliations

David Kaslow is affiliated with PATH, Bank of America Private Bank, Vical, Inc., Merck & Co., Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David Kaslow. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David Kaslow's profile does not indicate a business or promotional relationship of any kind between RelSci and David Kaslow.